<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007093</url>
  </required_header>
  <id_info>
    <org_study_id>EXPLORE-001</org_study_id>
    <nct_id>NCT05007093</nct_id>
  </id_info>
  <brief_title>Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib</brief_title>
  <official_title>An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yansong Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally&#xD;
      advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in glucose metabolism</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Evaluated by maximum standard uptake value (SUVmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>DTC - Differentiated Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride</intervention_name>
    <description>If intolerance occurs, the dose can be downregulated</description>
    <arm_group_label>Anlotinib hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathology confirmed the locally advanced or metastatic differentiated thyroid&#xD;
             cancer.At least have a measurable lesions (RECIST1.1)&#xD;
&#xD;
          -  Age:18-70 years old ECOG PS: 0-1. Life expectancy of at least 6 months&#xD;
&#xD;
          -  (1) The tumor cannot be completely removed, and the residual thyroid tissue is wide&#xD;
             and is not suitable for further iodine treatment. (2) The lesion is free from iodine.&#xD;
             (3) Cumulative RAI (radioactive iodine) dose ≥ 600 mci or 22 Gbq. (4) Radiology&#xD;
             examination confirmed that disease progression in 18 months after RAI treatment.&#xD;
&#xD;
          -  Pregnancy test (serum or urine) must be carried out within 7 days, and the test&#xD;
             results must be negative. The inclusion patient should take appropriate contraceptive&#xD;
             measures during the study and till 6 months after the last administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received external radiotherapy or iodine-131 therapy in recent 3&#xD;
             months, or plan to receive other systemic anti-tumor therapy or anti-tumor therapy&#xD;
             with traditional Chinese medicine during the study period.&#xD;
&#xD;
          -  Patients with other malignant tumors within 5 years or currently. Except primary&#xD;
             cervical cancer, non-melanoma skin cancer and superficial bladder tumor.&#xD;
&#xD;
          -  The toxicity of CTCAE (4.0) above grade 1 was not alleviated, excluding patients with&#xD;
             neurotoxicity (≤ grade 2) and alopecia caused by oxaliplatin.&#xD;
&#xD;
          -  With factors affecting oral administration (such as swallow, chronic diarrhea, etc.).&#xD;
&#xD;
          -  Patients with pleural effusion or ascites causing respiratory syndrome (CTCAE2 level&#xD;
             above).&#xD;
&#xD;
          -  Patients who underwent major surgery, open biopsy or significant traumatic injury&#xD;
             within 4 weeks.&#xD;
&#xD;
          -  Regardless of the severity, patients with any physical signs or history of bleeding,&#xD;
             patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four&#xD;
             weeks prior to the first administration, or patients with unhealed wounds, fractures,&#xD;
             ulcers.&#xD;
&#xD;
          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such&#xD;
             as cerebrovascular accident (including transient ischemic attack), deep vein&#xD;
             thrombosis and pulmonary embolism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan-Song Lin, MD</last_name>
      <phone>+86-10-69155610</phone>
      <email>linys@pumch.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Yansong Lin</investigator_full_name>
    <investigator_title>Prof. M.D.</investigator_title>
  </responsible_party>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

